GCP
CTSO icon

GSA Capital Partners’s Cytosorbents Corp CTSO Stock Holding History

GSA Capital Partners’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-148,374
Closed -$95K – 1806
2025
Q4 		$95K Buy
148,374
+36,157
+32% +$27.8K 0.01% 1534
2025
Q3 		$105K Buy
+112,217
New +$111K 0.01% 1518
2025
Q2 		– Sell
-53,030
Closed -$53K – 1802
2025
Q1 		$53K Buy
+53,030
New +$55.9K ﹤0.01% 1544
2022
Q2 		– Sell
-131,655
Closed -$420K – 1457
2022
Q1 		$420K Buy
131,655
+118,652
+912% +$425K 0.06% 655
2021
Q4 		$54K Buy
+13,003
New +$73K 0.01% 1348
2020
Q2 		– Sell
-75,869
Closed -$586K – 700
2020
Q1 		$586K Buy
75,869
+10,899
+17% +$55K 0.15% 105
2019
Q4 		$250K Buy
64,970
+32,150
+98% +$140K 0.03% 1148
2019
Q3 		$165K Buy
+32,820
New +$191K 0.02% 1211
2019
Q2 		– Sell
-16,882
Closed -$128K – 1487
2019
Q1 		$128K Buy
+16,882
New +$131K 0.01% 1309

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

GSA Capital Partners's CTSO Position: Q1 2026 in Review

GSA Capital Partners sold out of Cytosorbents Corp (CTSO) in Q1 2026, closing a stake of 148,374 shares — an estimated $95K sold.

GSA Capital Partners first reported a position in CTSO in Q1 2019 and held it in 9 quarters. The position peaked at $586K in Q1 2020. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.

  • GSA Capital Partners reported no remaining Cytosorbents Corp position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 148,374 Cytosorbents Corp shares in Q1 2026, an estimated $95K.
  • GSA Capital Partners first reported a position in Cytosorbents Corp in Q1 2019 and held it in 9 quarters.
  • GSA Capital Partners's Cytosorbents Corp position peaked at $586K in Q1 2020.
  • 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.